Eisai Clinical Trials

Phase II Extension Study of E7389 for Locally Advanced or Metastatic Breast Cancer

E7389-J081-224

Study Overview

E7389
eribulin mesilate
NCT00965523
Jan 2008 - Jan 2011
Breast Cancer
Number of Subjects With Adverse Events. [ Time Frame: Every week during treatment and up to 30 days after last dose of study treatment ]

  • Females (age 20 years to 74 years)

  • Completed

  • Phase 2

  • Japan

Results

CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Protocol
SAP
Sample CRF
Full CSR